Css LLC Abb Vie Inc. Transaction History

Css LLC

$999 Million
Q3 2024

A detailed history of Css LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Css LLC holds 3,200 shares of ABBV stock, worth $563,840. This represents 0.06% of its overall portfolio holdings.

Number of Shares

3,200

Previous 5,000 36.0%

Holding current value

$563,840

Previous $857,000 26.37%

% of portfolio

0.06%

Previous 0.08%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$163.84 - $199.33 $294,912 - $358,794	-1,800 Reduced 36.0%	3,200 $631,000
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $773,950 - $903,800	5,000 New	5,000 $857,000
Q3 2023 Nov 14, 2023	BUY	$133.59 - $154.65 $332,505 - $384,923	2,489 New	2,489 $371,000
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $102,268 - $117,294	-762 Reduced 17.88%	3,500 $470,000
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $536,630 - $665,807	-4,066 Reduced 48.82%	4,262 $691,000
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $53,715 - $67,965	500 Added 6.39%	8,328 $1.13 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $266,000 - $301,950	2,500 Added 46.92%	7,828 $845,000
Q2 2021 Aug 16, 2021	SELL	$105.21 - $117.21 $104,473 - $116,389	-993 Reduced 15.71%	5,328 $600,000
Q1 2021 May 17, 2021	BUY	$102.3 - $112.62 $646,638 - $711,871	6,321 New	6,321 $684,000
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $209,104 - $261,634	-2,899 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $2.2 Million - $2.44 Million	-24,726 Reduced 89.51%	2,899 $274,000
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $2.48 Million - $2.93 Million	27,625 New	27,625 $2.56 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $312B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Css LLC, based on Form 13F filings with the SEC.

News

Stay updated on Css LLC with notifications on news.

Account